 |
97 Diseases |  |
239 Trials |
|
239 Trials |  |
14341 News |  |
| «12...155156157158159160161162163164165166167 |
- |||||| rivaroxaban / Generic mfg., fondaparinux / Generic mfg.
Enrollment open: Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux (clinicaltrials.gov) - Apr 25, 2012
P3, N=506, Recruiting, Sponsor: GWT-TUD GmbH
Not yet recruiting --> Recruiting
- rivaroxaban / Generic mfg., erythromycin / Generic mfg.
Enrollment change: A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function (clinicaltrials.gov) - Apr 18, 2012
P1, N=29, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting N=24 --> 29
- | rivaroxaban / Generic mfg., erythromycin / Generic mfg.
Trial completion: A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function (clinicaltrials.gov) - Apr 18, 2012
P1, N=29, Completed, Sponsor: Janssen Research & Development, LLC
N=24 --> 29 Recruiting --> Completed
- rivaroxaban / Generic mfg., warfarin / Generic mfg.
Enrollment change: A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers (clinicaltrials.gov) - Apr 5, 2012
P1, N=46, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed N=34 --> 46
- ||| rivaroxaban / Generic mfg.
Trial completion: Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants (clinicaltrials.gov) - Mar 28, 2012
P1, N=55, Completed, Sponsor: Janssen Scientific Affairs, LLC
N=34 --> 46 Active, not recruiting --> Completed
- rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Enrollment open: REVANT: Reversal of the Antithrombotic Action of New Oral Anticoagulants (clinicaltrials.gov) - Mar 8, 2012
P4, N=10, Recruiting, Sponsor: Gines Escolar
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Biomarker, Trial completion: A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1) (clinicaltrials.gov) - Feb 19, 2012
P1, N=42, Completed, Sponsor: Merck
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients (clinicaltrials.gov) - Jan 23, 2012
P3, N=60, Completed, Sponsor: Bayer
- ||| rivaroxaban / Generic mfg.
New P3 trial: Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients (clinicaltrials.gov) - Jan 23, 2012
P3, N=40, Completed, Sponsor: Bayer
- ||| rivaroxaban / Generic mfg., warfarin / Generic mfg.
New P1 trial: Switching Study From Warfarin to Rivaroxaban (clinicaltrials.gov) - Jan 8, 2012
P1, N=96, Completed, Sponsor: Bayer
- |||||||||| rivaroxaban / Generic mfg., fondaparinux / Generic mfg.
New P3 trial: Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux (clinicaltrials.gov) - Dec 22, 2011
P3, N=506, Recruiting, Sponsor: GWT-TUD GmbH
- rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
New P4 trial: REVANT: Reversal of the Antithrombotic Action of New Oral Anticoagulants (clinicaltrials.gov) - Nov 7, 2011
P4, N=10, Recruiting, Sponsor: Gines Escolar
- ||| rivaroxaban / Generic mfg.
New P1 trial: Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants (clinicaltrials.gov) - Nov 1, 2011
P1, N=55, Completed, Sponsor: Janssen Scientific Affairs, LLC
- ||||||| rivaroxaban / Generic mfg.
Trial completion: Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study (clinicaltrials.gov) - Oct 18, 2011
P3, N=4833, Completed, Sponsor: Bayer
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| rivaroxaban / Generic mfg.
New P2 trial: X-PLORER: Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (clinicaltrials.gov) - Sep 27, 2011
P2, N=108, Completed, Sponsor: Bayer
- | rivaroxaban / Generic mfg.
New P1 trial: Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban (clinicaltrials.gov) - Sep 15, 2011
P1, N=28, Completed, Sponsor: Bayer
- || Fraxiparine (nadroparin) / Aspen
New P3 trial, Surgery: DARINA: Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery (clinicaltrials.gov) - Sep 6, 2011
P3, N=150, Not yet recruiting, Sponsor: Martini Hospital Groningen
- ||||||| rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
Trial completion: Dose-confirmatory Bridging Study in Total Hip Replacement (clinicaltrials.gov) - Aug 8, 2011
P3, N=402, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed